Cell-Free Synthesis Meets Antibody Production: A Review

Antibodies

Marlitt Stech²  Stefan Kubick¹ 

[1] Fraunhofer Institute for Cell Therapy and Immunology (IZI), Branch Bioanalytics and Bioprocesses Potsdam-Golm (IZI-BB), Am Mühlenberg 13, 14476 Potsdam, Germany; E-Mail

关键词: cell-free;    cell-free protein synthesis;    antibody;    antibody fragment;    scFv;    disulfide bond formation;    microsomal vesicles;    eukaryotic lysate;   

DOI  :  10.3390/antib4010012

来源: mdpi

【 摘 要 】

Engineered antibodies are key players in therapy, diagnostics and research. In addition to full size immunoglobulin gamma (IgG) molecules, smaller formats of recombinant antibodies, such as single-chain variable fragments (scFv) and antigen binding fragments (Fab), have emerged as promising alternatives since they possess different advantageous properties. Cell-based production technologies of antibodies and antibody fragments are well-established, allowing researchers to design and manufacture highly specific molecular recognition tools. However, as these technologies are accompanied by the drawbacks of being rather time-consuming and cost-intensive, efficient and powerful cell-free protein synthesis systems have been developed over the last decade as alternatives. So far, prokaryotic cell-free systems have been the focus of interest. Recently, eukaryotic in vitro translation systems have enriched the antibody production pipeline, as these systems are able to mimic the natural pathway of antibody synthesis in eukaryotic cells. This review aims to overview and summarize the advances made in the production of antibodies and antibody fragments in cell-free systems.

【 授权许可】

CC BY   
© 2015 by the authors; licensee MDPI, Basel, Switzerland.